A Phase 3 interventional study of AP301 and AP301 Low Dose in Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis and ESRD (End-Stage Renal Disease), sponsored by Alebund Pharmaceuticals. Recruiting at 42 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-01-29.
Sponsored by Alebund Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Hyperphosphatemia with a site in China — 6 open to participants now, 6 under way, 1 of them phase 3. Hyperphosphatemia · China.
Among the 18 studies in Hyperphosphatemia with a site in China, this one is the 3rd largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2025, is one of 7 in phase 3, and was the 15th registered.
173 studies on the registry are indexed under Hyperphosphatemia; 16 are open to participants now.
Browse Hyperphosphatemia studies →6 of the 18 studies in Hyperphosphatemia with a site in China are open now. Recruiting first, the newest first:
R1 Therapeutics · Sites in China, United States
Ages 18+
Jemincare · Sites in China
Ages 18+
Limeng Chen · Sites in China
Huashan Hospital · Sites in China
Peking University People's Hospital · Sites in China
Ages 18–100
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 13 Hyperphosphatemia studies recruiting now, 11 (85%) set no upper age limit and 2 (15%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 7 · Phase 4 1
First in 2011; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 264 is above the median of 101 across 143 interventional studies indexed under Hyperphosphatemia.
Median enrollment 158 across the 15 interventional studies, 200 across the 3 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 18 have an industry lead sponsor. The 10 most frequent:
Alebund Pharmaceuticals is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Alebund Pharmaceuticals has 3 studies filed under Hyperphosphatemia — fewer than ten, so there is no comparison to draw.
2 of the studies in Hyperphosphatemia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06712654R1 TherapeuticsA Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia | 2027-02-28 |
| NCT07776119Peking University People's HospitalReal-World Efficacy and Safety of Tenapanor Plus Phosphate Binders in Hemodialysis Patients With Hyperphosphatemia | 2027-04-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Hyperphosphatemia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if AP301 could work in the patients receiving maintenance dialysis with elevated blood phosphate. The main questions it aims to answer are:
The researchers will compare AP301 to an ineffective comparator (a look-alike substance that contains low dose AP301) to see if AP301 works to treat elevated blood phosphate.
In the study, the patients will experience the following stages in a chronicle order:
In the first 32 weeks, the dose of AP301 will be adjusted upwards or downwards based on the patient's blood phosphate level and the study doctor's judgment.
If the participant has a blood phosphate level above or below a certain level, they may receive additional treatment to lower the blood phosphate level.
Key Inclusion Criteria:
Patients who receive phosphate-lowering drugs over 4 weeks and their serum phosphate level is:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood phosphate-lowering medication containing iron
Drug: AP301
A blood phosphate-lowering medication containing iron, but with a low dose considered as ineffective
Drug: AP301 Low Dose
Three times a day, administered orally with three meals at a daily dose level from 2.7g to 9.0g
Three times a day, administered orally with three meals at a daily dose level from 0.075g to 0.25g
Change in serum phosphate concentrations in the AP301 and the AP301 low dose groups
The amount of phosphate in the blood will be measured with a standard laboratory test. The change in phosphate levels will be compared between the group receiving AP301 and the group receiving AP301 low dose.
Time frame: From Baseline to the end of Week 8
Chang in serum phosphate concentrations in the AP301 maintenance dose and the AP301 low dose groups
The amount of phosphate in the blood will be measured with a standard laboratory test. The change in phosphate levels will be compared between the group receiving AP301 maintenance dose and the group receiving AP301 low dose.
Time frame: From the beginning of Week 33 to the end of Week 35
Change in serum phosphate concentrations over time throughout the study
Time frame: From Baseline to the end of Week 35
Change in serum calcium (Ca) and intact parathyroid hormone levels over time
The amount of calcium and intact parathyroid hormone (iPTH) in the blood will be measured with standard laboratory tests.
Time frame: From Baseline to the end of Week 35
Number of adverse events
Time frame: From Baseline to Follow-up (Up to 37 weeks)
Change in QT intervals measured by 12-lead electrocardiagram test over time
The duration of QT intervals will be measured with a standard 12-lead electrocardiagram test.
Time frame: From Baseline to the end of Week 35
Change in the health-related quality of life questionnaires of EQ-5D-5L in Chinese patients only
The change in the scores of the questionnaire EuroQol 5-Dimension 5-Level (EQ-5D-5L), including the health state index score (the higher, the better quality of life) and the visual anaglog scale (ranging from 0 to 100; the higher, the better quality of life).
Time frame: From Baseline to Week 33
Change in the health-related quality of life questionnaires of KDQoL-36 in Chinese only
The change in the scores of the questionnaire Kidney Disease Quality of Life 36-item short form (KDQoL-36). The score ranges from 0 to 100 for five domains, with higher scores indicating better quality of life.
Time frame: From Baseline to Week 33
Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.
Of 21 phase 3 interventional studies under Hyperphosphatemia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 22. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AP301 peptide
Alebund Pharmaceuticals